ODC 0501

Drug Profile

ODC 0501

Alternative Names: DC vaccine - ODC Therapy; Dendritic cell vaccine - ODC Therapy; ODC-0501

Latest Information Update: 28 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor Research Institute; Rockefeller University
  • Developer Baylor Research Institute; ODC Therapy
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 28 Mar 2008 ODC 0501 is still in phase I/II trials for Malignant melanoma in USA
  • 31 Jul 2005 Phase-I/II clinical trials for Malignant melanoma in USA (Parenteral)
  • 30 Nov 2004 Phase-I clinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top